Leading the Way in Life Science Technologies

GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

FDA Holds Public Discussion of User Fee Program for Biosimilars

Initiative is one step in agency’s road to developing the final abbreviated approval pathway for biosimilars.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »